Core Viewpoint - The announcement reveals that the controlling shareholder, Yan Jinyuan, and the actual controller, Wang Shi, will transfer approximately 18.52 million shares, representing 7% of the company's total equity, to Quwizhihe at a price of RMB 9.45 per share, totaling around RMB 175 million. This transaction reflects confidence in the company's future development and investment value, without changing the controlling shareholder structure [1]. Group 1 - The controlling shareholder and actual controller will transfer approximately 18.52 million shares, which is 7% of the company's total equity [1] - The transfer price is set at RMB 9.45 per share, amounting to a total of approximately RMB 175 million [1] - The transaction is based on Quwizhihe's confidence in the company's future and investment value [1]

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the research, production, and sales of medical devices. It is recognized as a national industrialization base for multi-parameter monitors and a national champion enterprise in manufacturing [1]. - The company’s monitoring equipment is utilized in thousands of medical institutions across China [1]. Product Categories - The company offers a diverse range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems, applicable in various medical settings such as general wards, emergency rooms, ICUs, CCUs, and operating rooms [2]. - In home healthcare, the company provides wearable medical products like pulse oximeters and ultrasound Doppler fetal heart monitors, used in family health care, community medical services, and outdoor activities [2]. - In the renal medical field, the company has a complete industrial chain with eight consumable bases and a channel platform, offering products like blood dialysis devices, dialysis filters, and disinfectants, widely used in treating acute and chronic renal failure [2]. R&D Focus - The company aims to enhance its product development by integrating smart technology to address clinical needs and create differentiated solutions, transitioning from functional integration to intelligent decision-making [3]. Competitive Advantages - The P series high-end monitors feature unique parameters, including EEG and regional blood oxygen saturation monitoring, and possess industry-leading technologies to address key challenges in surgical anesthesia [4]. - The company has developed non-invasive brain monitoring technologies for operating rooms and ICUs, focusing on multi-channel EEG monitoring, real-time anesthesia depth monitoring, and brain oxygen saturation monitoring [5][6]. Market Insights - As of 2024, the number of patients undergoing hemodialysis in China is projected to reach 1.027 million, maintaining an annual compound growth rate of approximately 12% over the past decade [7]. - The domestic market for blood dialysis equipment is expected to grow due to the recovery of hospital operations and the advancement of blood dialysis center projects, with domestic brands accounting for about 50% of the market value in 2025 [7]. Product Advantages - The company’s D800 series blood dialysis devices meet diverse patient needs and integrate monitoring capabilities, supporting remote management and compliance with new monitoring requirements without additional modules [8]. - The D800Plus model is the first domestic three-pump device capable of mixed dilution dialysis, improving treatment outcomes [8][9]. Business Developments - The company has obtained registration for its fully automatic home peritoneal dialysis machine and single-use peritoneal dialysis tubing, with sales already initiated [10]. - Recent product launches include the D800 series blood dialysis devices, P series modular monitors, and various innovative medical devices, some of which have received industry accolades [11]. Policy Impact - The implementation of the "old-for-new" policy for medical devices positively impacts the company’s monitoring equipment business, increasing demand for upgrades in public hospitals and grassroots medical institutions [12][13].

广东宝莱特医用科技股份有限公司 简式权益变动报告书 上市公司名称：广东宝莱特医用科技股份有限公司 上市地点：深圳证券交易所 股票简称：宝莱特 股票代码：300246 信息披露义务人1：燕金元 住所\通讯地址：广东省珠海市高新区永和路9号 权益变动性质：股份减少（协议转让） 信息披露义务人2：王石 住所\通讯地址：广东省珠海市高新区永和路9号 权益变动性质：股份减少（协议转让） 签署日期：2026年1月12日 1 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市公司收购报告书》 及相关法律法规、规范性文件之规定编写。 二、截至本报告书签署之日，信息披露义务人签署本报告书已获得必要的授权和批准， 其履行亦不违反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券的公 司信息披露 ...

证券代码：300246 证券简称：宝莱特 公告编号：2026-002 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于控股股东、实际控制人拟协议转让部分股份暨股东权益变动的提 示性公告 控股股东、实际控制人燕金元先生及控股股东一致行动人、实际控制人王石 女士保证向公司提供的信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、广东宝莱特医用科技股份有限公司（以下简称"公司"）控股股东、实 际控制人燕金元先生及控股股东一致行动人、实际控制人王石女士拟通过协议转 让方式将其持有的公司无限售流通股 18,520,600 股，系公司首次公开发行前持有 股份，占公司目前总股本的 7.00%，以人民币 9.45 元/股的价格转让给浙江衢威 智合控股合伙企业（有限合伙）（以下简称"衢威智合"）。双方于 2026 年 1 月 12 日签署《股份转让协议》，转让价格不低于本次股份转让协议签署日前一 个交易日收盘价格的 80%。 2、本次协议转让过户前，衢威智合未持有公司 ...

广东宝莱特医用科技股份有限公司 简式权益变动报告书 上市公司名称：广东宝莱特医用科技股份有限公司 上市地点：深圳证券交易所 股票简称：宝莱特 股票代码：300246 四、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务人外，没有 委托或者授权任何其他人提供未在本报告书中列载的信息和对本报告书做出任何解释或者 说明。 五、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗漏，并对其 真实性、准确性、完整性承担法律责任。 信息披露义务人：浙江衢威智合控股合伙企业（有限合伙） 住所\通讯地址：浙江省衢州市凤栖路9号1幢107-1室 权益变动性质：股份增加（协议转让） 签署日期：2026年1月12日 1 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市公司收购报告书》 及相关法律法规、规范性文件之规定编写。 二、截至本报告书签署之日，信息 ...

Market Overview - The market showed strong fluctuations throughout the day, with all three major indices rising over 1%, and the Shanghai Composite Index achieving a 17-day consecutive rise [1] - AI application sectors experienced a significant surge, with stocks like BlueFocus and Hand Information hitting the daily limit [1] - The commercial aerospace concept continued its strong performance, with China Satellite and China Satcom both reaching new highs [1] - The brain-computer interface concept was also active, with stocks like DaoTech and Yanshan Technology hitting the daily limit [1] - Over 4,100 stocks in the Shanghai, Shenzhen, and Beijing markets rose, with a total transaction volume of 3.64 trillion, setting a new record for daily trading in A-shares [1] AI Marketing - The AI marketing concept saw a wave of limit-up stocks, including Gravity Media, Leo Holdings, and BoRui Communication [4] - Elon Musk announced on social media that he would open-source the latest content recommendation algorithm for the X platform within a week, interpreted by the market as his entry into the GEO space [4] - DeepSeek is set to release its next-generation flagship AI model, DeepSeek V4, in February, which reportedly outperforms major models like Anthropic Claude and OpenAI GPT series in programming capabilities [4][7] - Anthropic's Claude Code received a significant update, marking a new phase in global AI programming competition [4] Aerospace Sector - The aerospace sector continued to rise, with stocks like Luxin Investment, Goldwind Technology, and Daye Shares hitting the daily limit [10] - China applied for frequency resources for over 200,000 satellites, indicating a strategic national-level initiative [11] - Experts believe that the establishment of the Radio Innovation Institute will accelerate the 6G process, integrating satellite networks with ground communication networks [14] AI Medical - The AI medical sector also performed well, with companies like Meinian Health and Dean Diagnostics seeing consecutive gains [15] - OpenAI launched "ChatGPT Health," a health-related dialogue space that connects electronic medical records and health applications [15] - The demand for AI in healthcare is expected to grow significantly, driven by an aging population and an increase in chronic disease patients [18]

Market Performance - The medical device sector increased by 1.89% on January 12, with Kangzhong Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - Kangzhong Medical (688607) closed at 53.99, up 20.00% with a trading volume of 154,300 shares and a transaction value of 817 million [1] - Laijing Co. (301093) closed at 57.68, up 19.99% with a trading volume of 139,400 shares and a transaction value of 753 million [1] - Baolait (300246) closed at 10.91, up 17.19% with a trading volume of 499,500 shares and a transaction value of 523 million [1] Top Losers - Rejing Bio (688068) closed at 188.88, down 8.29% with a trading volume of 26,300 shares and a transaction value of 509 million [2] - Wuzhou Medical (301234) closed at 44.06, down 7.53% with a trading volume of 42,900 shares and a transaction value of 192 million [2] - New Industry (300832) closed at 60.41, down 3.84% with a trading volume of 53,700 shares and a transaction value of 327 million [2] Fund Flow Analysis - The medical device sector saw a net inflow of 199 million from institutional investors, while retail investors experienced a net inflow of 41.84 million [2] - Retail funds showed a net outflow of 241 million, indicating a shift in investment behavior [2] Individual Stock Fund Flow - Lepu Medical (300003) had a net inflow of 167 million from institutional investors, representing 5.74% of total trading [3] - Yuyue Medical (002223) experienced a net inflow of 156 million from institutional investors, with a net outflow of 74.75 million from retail investors [3] - Union Medical (688271) saw a net inflow of 104 million from institutional investors, while retail investors had a net outflow of 53.01 million [3]

Group 1 - The core point of the news is that Baolait Medical Technology Co., Ltd. experienced a stock price increase of 5.15%, reaching 8.99 yuan per share, with a total market capitalization of 2.379 billion yuan as of January 8 [1] - The company, founded on June 28, 1993, and listed on July 19, 2011, specializes in the research, production, sales, and service of medical device products, with main business revenue composition being 77.51% from blood dialysis products, 21.39% from monitoring devices, and 1.10% from other products [1] Group 2 - From the perspective of Baolait's top ten circulating shareholders, Citic Prudential Fund has a fund that entered the top ten shareholders, holding 1.055 million shares, which is 0.5% of the circulating shares, with an estimated floating profit of approximately 464,200 yuan [2] - The Citic Prudential Multi-Strategy Mixed Fund (LOF) A, established on June 16, 2017, has a latest scale of 1.133 billion yuan, with a year-to-date return of 0.9% ranking 7345 out of 8825 in its category, a one-year return of 49.64% ranking 2022 out of 8084, and a cumulative return since inception of 148.56% [2]

证券代码：300246 证券简称：宝莱特 公告编号：2026-001 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025年第四季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、宝莱转债（债券代码：123065）转股期限为 2021 年 3 月 11 日至 2026 年 9 月 3 日，最新有效的转股价格为人民币 23.97 元/股。 一、可转换公司债券发行上市概况 1、可转债发行上市基本情况 经深圳证券交易所创业板上市委2020年第8次审议会议审核通过，并经中国 证监会证监许可[2020]1831号文同意注册。公司于2020年9月4日向不特定对象发 行了219万张可转换公司债券，每张面值为人民币100元，发行总额为人民币2.19 亿元。本次发行的可转换公司债券向发行人在股权登记日收市后中国证券登记结 算有限责任公司深圳分公司登记在册的原股东优先配售，原股东优先配售后余额 部分（含原股东放弃优先配售部分）通过深圳证券交易所交易系统网上向社会公 众投资者发行，余额由保荐机构（主承销商）包 ...

Group 1 - The core viewpoint of the news is that Baolait Medical Technology Co., Ltd. has seen a stock price increase of 5.31%, reaching 8.53 CNY per share, with a total market capitalization of 2.257 billion CNY as of January 5 [1] - The company, founded on June 28, 1993, and listed on July 19, 2011, specializes in the research, production, sales, and service of medical device products [1] - The main revenue composition of the company includes hemodialysis products at 77.51%, monitoring equipment at 21.39%, and other products at 1.10% [1] Group 2 - From the perspective of Baolait's top ten circulating shareholders, Citic Prudential Fund has entered the list with its multi-strategy mixed fund (LOF) A, holding 1.055 million shares, which is 0.5% of the circulating shares [2] - The fund has achieved a year-to-date return of 45.48%, ranking 1493 out of 8155 in its category [2] - The fund manager, Wang Ying, has been in the position for 8 years and 326 days, with the fund's total asset size at 4.904 billion CNY [3]